Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

Howard S. Hochster; Michael D. Green; Ronald H. Blum; James C. Wernz; James L. Speyer; Franco M. Muggia

doi:10.1007/BF00179596

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

Howard S. Hochster
, Michael D. Green
, Ronald H. Blum
, James C. Wernz
, James L. Speyer
, Franco M. Muggia

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.

Original language	English
Pages (from-to)	275-278
Number of pages	4
Journal	Investigational New Drugs
Volume	4
Issue number	3
DOIs	https://doi.org/10.1007/BF00179596
State	Published - Sep 1986
Externally published	Yes

Keywords

4-demethoxydaunorubicin
idarubicin
non-small cell lung cancer
oral cytotoxic
phase II clinical trial

Access to Document

10.1007/BF00179596

Cite this

@article{9977a024c1f94197ad5c00a79c386022,

title = "Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial",

abstract = "Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.",

keywords = "4-demethoxydaunorubicin, idarubicin, non-small cell lung cancer, oral cytotoxic, phase II clinical trial",

author = "Hochster, \{Howard S.\} and Green, \{Michael D.\} and Blum, \{Ronald H.\} and Wernz, \{James C.\} and Speyer, \{James L.\} and Muggia, \{Franco M.\}",

year = "1986",

month = sep,

doi = "10.1007/BF00179596",

language = "English",

volume = "4",

pages = "275--278",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

AU - Hochster, Howard S.

AU - Green, Michael D.

AU - Blum, Ronald H.

AU - Wernz, James C.

AU - Speyer, James L.

AU - Muggia, Franco M.

PY - 1986/9

Y1 - 1986/9

N2 - Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.

AB - Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxy-daunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.

KW - 4-demethoxydaunorubicin

KW - idarubicin

KW - non-small cell lung cancer

KW - oral cytotoxic

KW - phase II clinical trial

UR - https://www.scopus.com/pages/publications/0023026033

U2 - 10.1007/BF00179596

DO - 10.1007/BF00179596

M3 - Article

C2 - 3469171

AN - SCOPUS:0023026033

SN - 0167-6997

VL - 4

SP - 275

EP - 278

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; Phase II trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this